AEON Biopharma, Inc. (AEON) Stock Analysis & Investment Frameworks
AEON Biopharma, Inc. (AEON) stock analysis on Invetso. Review AEON Biopharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
AEON Biopharma, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
AEON Biopharma, Inc. Key Financial Metrics
- Market Cap: $11.66M
- Revenue: $N/A
- ROE: 204.18%
- ROIC: 1699.74%
- Dividend Yield: N/A
About AEON Biopharma, Inc.
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
AEON Biopharma, Inc. Investment Frameworks
Invetso analyzes AEON Biopharma, Inc. (AEON) across the following frameworks:
- AEON Biopharma, Inc. 10Y Growth Potential
- AEON Biopharma, Inc. Scenario Analysis
- AEON Biopharma, Inc. Risks & Opportunities
- AEON Biopharma, Inc. Economic Moat
- AEON Biopharma, Inc. Business Model
- AEON Biopharma, Inc. Management
- AEON Biopharma, Inc. SWOT Analysis
- AEON Biopharma, Inc. Porter's 5 Forces
- AEON Biopharma, Inc. PESTLE Analysis
- AEON Biopharma, Inc. ESG Analysis